| Date | Title | Description |
| 08.04.2021 | OTONOMY, INC.
Otonomy Announces Pricing of $30.1 Million Public Offering | SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering ... |
| 28.07.2017 | A race is underway to repair our hearing — with medicine | On any bustling city street, in the middle of the afternoon, it’s probably the case that half or more people are wearing earbuds, while the rest are abiding the noise pollution all around them. No one thinks twice about it, either.
The real... |
| 26.09.2016 | Can a Pill Fix Your Hearing? | Listen up, baby boomers (and others): Your damaged hearing may soon be improved—and it won’t require inserting a beige gizmo in your ear. Advances in molecular biology and bioinformatics have led to an explosion of research on the causes of... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 12.01.2016 | Otonomy Inc. Announces Close of $115 Million Public Offering | San Diego drug developer Otonomy Inc. announced Jan 12 the closing of its $115 million public offering of stock.
The previously announced public offering included 5,750,000 shares of its common stock, and an additional 750,000 shares (sold ... |
| 15.10.2015 | Third Rock hearing loss startup Decibel Therapeutics launches with $52M | Indeed, Third Rock companies generally take this broad scale approach to their respective fields – take Bluebird Bio’s approach to gene therapy, or Constellation Pharmaceuticals’ approach to epigenetics.
Starr, a cofounder at Third Rock, sa... |
| 14.08.2014 | Otonomy Announces $100M IPO | Venture-backed Otonomy, a San Diego, CA-based developer of drug therapies for the inner and middle ear, announced a $100m initial public offering.
The biopharma company priced 6.25m shares of common stock at a price of $16.00 per share, whi... |
| 13.07.2014 | Fresh off Phase III success, Otonomy shoots for an $86M IPO | San Diego biotech Otonomy isn't biding its time, filing to go public in an $86.3 million IPO just three days after unveiling positive Phase III results for its lead drug.
The company, hardly short on cash after closing a $49 million Series ... |
| 30.04.2014 | Otonomy Inks $49M in Oversubscribed Round |
SAN DIEGO, CA, Biopharmaceutical company developing and commercializing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced it has secured $49 million in an oversubscribed Series D round.
>&... |
| 30.04.2014 | Otonomy Raises $49 Million in Oversubscribed Financing | |
| 30.04.2014 | Otonomy Secures $49M in Series D Financing | Otonomy, a San Diego, CA-based biopharmaceutical company developing therapeutics for diseases for the ear, secured $49m in Series D financing.
Backers included new investors Jennison Associates LLC (on behalf of clients), Perceptive Advisor... |
| 30.04.2014 |
Otonomy Gets $49M In New Funding
| San Diego-based biopharmaceuticals developer Otonomy--which is developing treatments for inner and middle ear disorders--has roped in a big, $49M funding, the company announced this morning. The Series D funding came from Jennison Associate... |
| 18.10.2013 | Health IT deals help push software deals to 12-year high but life science struggles | Here were the biggest health IT deals for the quarter based on data from the MoneyTree Report and Mercom Capital Group’s Healthcare IT report.
Evolent Health raised $100 million. EHR provider Practice Fusion raised $70 million. MedSynergies... |
| 04.09.2013 | Biopharma raises $46M to surmount treatment challenges for inner ear disorders | Among the symptoms of Meniere’s disease are sudden onset of vertigo, a sense of fullness or pressure in one or both ears, hearing loss and tinnitus.
About 628,000 people in the U.S. have been diagnosed with Meniere’s disease but about 2 per... |
| 04.09.2013 | Otonomy Completes $45.9M in Series C |
SAN DIEGO, CA, Clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that it completed a Series C financing which raised $45.9 million in new fu... |
| 04.09.2013 |
Otonomy Lands $45.9M
| San Diego-based biopharmaceuticals firm Otonomy announced this morning that it has raised $45.9M in a Series C, equity funding. According to the company, the funding was led by OrbiMed Advisors, and also included Aperture Venture Partners, ... |
| 04.09.2013 | Otonomy Completes $45.9M Series C Financing | Otonomy, Inc., a San Diego, CA-based clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, completed a $45.9m Series C financing.
The round was led by OrbiMed Adv... |
| 30.08.2010 |
Otonomy Raises $38.5M
| San Diego-based Otonomy, a biopharmaceuticals firm developing products to treat disorders of the inner and middle ear, announced today that it has raised $38.5M in a Series B financing. The round was led by Novo Ventures and RiverVest Ventu... |
| 30.08.2010 | Otonomy Closes $38.5M Series B Financing | Otonomy, Inc., a San Diego, CA-based clinical stage biopharmaceutical company developing novel drug therapies for disorders of the inner and middle ear, has closed a $38.5m Series B financing.
The round was co-led by Novo Ventures and River... |
| 11.06.2010 |
Otonomy Raises $10M
| San Diego-based Otonomy, which is developing treatments for Meniere's disease, said today that it has raised $10M in a Series A financing round. The round came from Avalon Ventures. According to Otonomy, the funding will go towards supporti... |
| 11.06.2010 | Otonomy Closes $10M Series A Financing | Otonomy, Inc., a San Diego, CA-based clinical stage biopharmaceutical company developing innovative drug therapies for disorders of the inner and middle ear, has closed a $10m Series A financing with Avalon Ventures.
The company’s core tech... |
| 09.06.2010 |
Otonomy Takes $10.5M
| San Diego-based Otonomy, a biopharmaceuticals firm developing drug therapies to treat inner and middle ear disorders, has raised $10.56M as part of an ongoing, $26.0M fundraising effort, according to a regulatory filing by the firm. Source ... |
| - | Biopharma raises $46M to surmount treatment challenges for inner ear disorders | Our love of iPods, iPhones and other personal audio devices means the problem of hearing loss is worsening. Otonomy has raised $45.9 million to advance its therapeutics to treat middle and inner ear disorders, such as Meniere’s disease and ... |
| - | Third Rock hearing loss startup Decibel Therapeutics launches with $52M | Third Rock Ventures is launching a startup geared at broadly treating hearing loss – leading a $52 million Series A for freshly christened Decibel Therapeutics.
The Boston company is developing drugs that can be directly injected into the i... |
| - | Health IT deals help push software deals to 12-year high but life science struggles | Investments in electronic health records, tools to help hospitals absorb physician practices and a group working with hospital systems to help them set up their own insurance plans. Those three health IT companies helped drive venture capit... |
